Mabwell, an innovation-driven biopharmaceutical company with a fully integrated pharmaceutical value chain, has received marketing authorization from the Indonesian Food and Drug Authority (BPOM) for its Adalimumab Injection 9MW0113, marketed in China as JUNMAIKANG. This marks the third overseas marketing approval Mabwell has secured in 2026.
Co-developed with Junshi Biosciences, 9MW0113 is the first Adalimumab biosimilar independently developed in China to receive BPOM approval. Mabwell has signed formal cooperation agreements for 9MW0113 in over ten countries and has submitted registration applications in multiple other markets, including Jordan and Peru, as part of its global commercialization strategy.
Indonesia, the most populous country in Southeast Asia, maintains rigorous regulatory standards as a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The approval of Mabwell’s biosimilar highlights the company’s commitment to expanding access to high-quality biologics and addressing unmet medical needs worldwide.
Mabwell focuses on developing effective and accessible therapies with an emphasis on oncology and aging-related diseases. Its mission is "Explore Life, Benefit Health," and its vision is "Innovation, from Ideas to Reality." The company’s capabilities span the entire pharmaceutical value chain, enabling it to support global development and commercialization of its therapies.
